<ul> <li>Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease.</li> <li>Results from the study will be presented at ASN Kidney Week 2023 November 1&…